Since PDPs have been shown to be useful for subtype differentiation for lung cancer, we decided to investigate whether nanoDSF-derived PDPs could also be used to discriminate EGFR alterations in GBM, which is important for determining therapy strategies. This evidence concerns the gene EGFR and lung cancer.